Storia in 2 fonti

AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days - AbbVie (NYSE:ABBV)

AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety in preventing menstrual migraines.

Raccontata da

fiercepharma.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.com17 h fa

What's Going On With AbbVie Stock Friday? - AbbVie (NYSE:ABBV)

AbbVie's Phase 3 atogepant trial for menstrual migraine met all endpoints with 0.80-day net symptom reduction versus placebo. Pending regulatory submission targets unmet need; expands CGRP franchise and supports $10.9B Apogee acquisition strategy for immunology.

Leggi questa versione → originale

fiercepharma.com1 g fa

AbbVie lines up Qulipta expansion with phase 3 win in untapped menstrual migraine indication

With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative Qulipta, also known as atogepant. | With positive phase 3 results in hand, AbbVie is one step…

Leggi questa versione → originale

What's Going On With AbbVie Stock Friday? - AbbVie (NYSE:ABBV)

AbbVie lines up Qulipta expansion with phase 3 win in untapped menstrual migraine indication

Timeline cronologica

AbbVie lines up Qulipta expansion with phase 3 win in untapped menstrual migraine indication

AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days - AbbVie (NYSE:ABBV)

What's Going On With AbbVie Stock Friday? - AbbVie (NYSE:ABBV)